| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Institute of Organic and Pharmaceutical Chemistry and
2 Institute of Biological Research and Biotechnology, The National Hellenic Research Foundation, 11635 Athens, Greece
3 Department of Biology and Biochemistry, University of Bath, Claverton Down, Bath BA2 7AY, UK
4 Institute of Biology, National Center for Scientific Research "Demokritos," 15310 Ag. Paraskevi, Athens, Greece
Reprint requests to: Demetres D. Leonidas, The Institute of Organic and Pharmaceutical Chemistry, The National Hellenic Research Foundation, 48 Vas. Constantinou Avenue, 11635 Athens, Greece; e-mail: ddl{at}eie.gr; fax: 30210-7273831.
(RECEIVED May 8, 2003; FINAL REVISION July 15, 2003; ACCEPTED July 16, 2003)
5 Present address: Cambridge Institute of Medical Research, MRC/Wellcome Trust Building, Cambridge CB2 2XY, UK. 
Article and publication are at http://www.proteinscience.org/cgi/doi/10.1110/ps.03196603.
 |
Abstract |
|---|
 TOP Abstract IntroductionResults and DiscussionMaterials and methodsReferences |
|---|
-phosphate group that binds to P1. 3',5'-ADP binds with the 5'-phosphate group in P1 and the adenosine in the B2 pocket. Two different binding modes are observed in the two RNase A molecules of the asymmetric unit for 2',5'-ADP. This inhibitor binds with either the 3' or the 5' phosphate groups in subsite P1, and in each case, the adenosine binds in two different positions within the B2 subsite. The two uridilyl inhibitors bind similarly with the uridine moiety in the B1 subsite but the placement of a different phosphate group in P1 (2' versus 3') has significant implications on their potency against RNase A. Comparative structural analysis of the RNase A, eosinophil-derived neurotoxin (EDN), eosinophil cationic protein (ECP), and human angiogenin (Ang) complexes with these and other phosphonucleotide inhibitors provides a wealth of information for structure-based design of inhibitors specific for each RNase. These inhibitors could be developed to therapeutic agents that could control the biological activities of EDN, ECP, and ANG, which play key roles in human pathologies. Keywords: Ribonuclease A inhibitors; structure-aided drug design; angiogenin; eosinophil-derived neurotoxin; eosinophil cationic protein
Abbreviations: RNase A, bovine pancreatic Ribonuclease A • Ang, angiogenin • EDN, eosinophil derived neurotoxin • ECP, eosinophil cationic protein • 3',5'-ADP, adenosine-3',5'-diphosphate, 2',5'-ADP, adenosine-2',5'-diphosphate, 5'-ADP, adenosine-5'-diphosphate, pdUppA-3'-p, 5'-phospho-2'-deoxyuridine 3-pyrophosphate (P'
5') adenosine 3'-phosphate • ppA-3'-p, 5'-diphosphoadenosine 3'-phosphate • ppA-2'-p, 5'-diphosphoadenosine 2'-phosphate • dUppA-3'-p • 2'-deoxyuridine 3'-pyrophosphate (P'5') adenosine • PEG, poly(ethylene glycol)
|
Introduction |
|---|
|
TOPAbstractIntroductionResults and DiscussionMaterials and methodsReferences |
|---|
In the last years, a potent class of inhibitors, the adenosine 5'-pyrophosphate derivatives, has been discovered (Leonidas et al. 1997, 1999; Russo et al. 1997; Russo and Shapiro 1999; Jardine et al. 2001). Crystallographic studies on the binding of such derivatives like ppA-3'-p (Ki = 0.24 mM), ppA-2'-p (Ki = 0.52 mM; Leonidas et al. 1997; Russo et al. 1997), dUppA (Ki = 11.3 µM; Jardine et al. 2001), and pdUppA-3'-p (Ki= 0.027 µM; Leonidas et al. 1999; Russo and Shapiro 1999), with RNase A have shown that the phosphate groups constitute the anchor points for the binding of these inhibitors to RNase A. The 5'-pyrophosphate group binds with the ß-phosphate at subsite P1, while the 2' or 3' adenylic phosphates bind at the peripheral phosphate-binding subsites Po and P2, respectively. The adenosine adopts the unusual syn conformation and binds at B2, while uridine is found at B1. These inhibitors are also potent against EDN, RNase 4, and Ang (Shapiro 1998; Russo and Shapiro 1999; Russo et al. 2001). However, recent structural studies of EDN complexes with three adenylic phosponucleotide inhibitors (Leonidas et al. 2001a), ECP in complex with 2',5'-ADP (Mohan et al. 2002) and Ang in complex with phosphate and pyrophosphate ions (Leonidas et al. 2001b) have shown that the binding mode of phosphonucleotides to these enzymes might differ considerably from the one observed in RNase A. Thus, although the interactions of a phosphate group at P1 were still the driving force for the binding of phosphoadenosine inhibitors to EDN and ECP, the position of the nucleotide base differs considerably depending on the nucleotide (Leonidas et al. 2001a; Mohan et al. 2002). Furthermore, in Ang, the pyrophosphate ion binds with one of the phosphate groups in P1 and the other directed towards the pyrimidine binding site B1 in contrast to the binding mode of pyrophosphate derivatives to RNase A (Leonidas et al. 2001b).
In the present study we are investigating the mode of binding of three adenylic (3',5'-ADP, 2',5'-ADP, and 5'-ADP) and two uridylyl (U-2'-p, U-3'-p) inhibitors to RNase A at high resolution. These structures give a detailed picture of the specificity of the ribonucleolytic active site towards phosphates and nucleotide bases and show the degree of flexibility of subsites B1 and B2. The high-resolution structures also provide the basis for a comparative structural analysis of EDN, ECP, and RNase A phosphonucleotide complexes and assist the process of the development of ribonucleolytic inhibitors specific for each RNase. Furthermore, the crystallographic data of the RNase A complexed with 2',5'-ADP and 5'-ADP at near atomic resolution (1.2 Å) revealed the positions of additional water molecules bound in the RNase A active site and indicated a complex water-mediated network of interactions between the inhibitors and the protein. This network may have important implications for the further development of new and more potent ribonucleolytic inhibitors.
|
Results and Discussion |
|---|
|
TOPAbstractIntroductionResults and DiscussionMaterials and methodsReferences |
|---|
atoms. In all free RNase A structures reported so far the side chain of the catalytic residue His119 adopts two conformations denoted as A (
1 = 
160°) and B (1 = -80°), which are related by a 100° rotation about the C–Cß bond and a 180° rotation about the Cß–C
bond (Borkakoti et al. 1982; Howlin et al. 1989; deMel et al. 1994). These conformations are dependent on the pH (Berisio et al. 1999) and the ionic strength of the crystallization solution (Fedorov et al. 1996). Conformation A is considered as the active conformation, which promotes catalysis, whereas conformation B is considered as the inactive conformation (Raines 1998). The side chain of His119 adopts conformation A in the 3',5'-ADP, 5'-ADP, U-2'-p, and U-3'-p complexes while in the 2',5'-ADP complex it is found in conformation B. Superposition of the structures of the RNase A–3',5'-ADP complex (molecules I and II of the asymmetric unit) on the structure of free RNase A at 1.1 Å resolution (PDB code 1KF2 [PDB] ; Berisio et al. 2002) reveals that 3',5'-ADP displaces two (molecule I) and three (molecule II) water molecules from the active site. Similarly, two water molecules are replaced upon binding of 2',5'-ADP (molec I and molec II) while three (molec I) and one (molec II) water molecules are replaced upon binding of 5'-ADP. Upon binding of U-2'-p, five (molec I) and four (molec II) water molecules are replaced while upon binding of U-3'-p, five water molecules are replaced in both molecules I and II of the asymmetric unit.
The RMSD between the positions of the C atoms of the 3',5'-ADP complex and those of the 2',5'-ADP, 5'-ADP, U-2'-p, and U-3'-p complexes are 0.46, 0.42, 0.46, and 0.54 Å respectively. The corresponding values within the complexes, 2',5'-ADP against 5'-ADP, U-2'-p, and U-3'-p are 0.24, 0.30, and 0.22 Å, respectively, whereas the RMSD between the 5'-ADP and U-2'-p, and U-3'-p complexes are 0.26 and 0.31 Å, respectively. In addition, the RMSD between the positions of the C atoms of the U-2'-p and U-3'-p complexes is 0.35 Å. Thus, it appears that the differences between the five complex structures are very small, mainly concentrated on the loop regions and are not related to the binding of the different inhibitors. The structures of the 3',5'-ADP, U-2'-p, and U-3'-p complexes are defined at 1.5 Å resolution and contain 389, 299, and 415 water molecules, respectively. The structures of the 2',5'-ADP, and 5'-ADP complexes are determined at a higher resolution (1.2 Å), and contain 558 and 540 water molecules, respectively. Numbering scheme definitions for all five inhibitors are presented in Figure 1
.
|
). The conformation of 3',5'-ADP when bound to RNase A is similar to that observed previously for adenosine nucleotides bound at B2 in the RNase A complexes with d(pA)4 (McPherson et al. 1986), d(ApTpApApG) (Fontecilla-Camps et al. 1994), and d(CpA) (Zegers et al. 1994), as well as to those frequently observed in the unbound and protein bound adenosines (Moodie and Thornton 1993). The glycosyl torsion angle adopts the anti conformation, and the rest of the backbone and phosphate torsion angles are in the preferred range for protein bound adenosines (Moodie and Thornton 1993). The torsion angle of 3',5'-ADP in RNase A molecule II is in the unusual sp range, but its value (18°) is close to the favorable +sc range (30°–90°; Table 1). The ribose is found in both molecules at the C2'-endo conformation.
|
) with the 5'-phosphate group in P1 involved in hydrogen bond interactions with Gln11, His12, Lys41, and Phe120, while the 3'-phosphate group is bound at the P2 subsite forming a hydrogen bond with Lys7 (Fig. 2A). The adenine is bound at the B2 subsite in a manner similar to that observed previously for other adenylic nucleotides bound to RNase A (McPherson et al. 1986; Fontecilla-Camps et al. 1994; Zegers et al. 1994). The adenine ring packs with its five-member ring against the imidazole ring of His119, which adopts conformation A (1 = 158°). The N6 group of adenine is in hydrogen-bonding distance from the side chain atoms of residues Gln69 and Asn71 (Table 2, observed only in RNase A molecule I).
|
|
). RNase A residues and 3',5'-ADP atoms are involved in 35 and 48 van der Waals contacts in molecules I and II, respectively.
The binding of 2',5'-ADP to RNase A
The 2',5'-ADP molecule is well defined within the electron density map in both RNase A molecules of the crystallographic asymmetric unit (Fig. 1B). The conformation of 2',5'-ADP is similar in the two RNase A molecules of the asymmetric unit and to that of 3',5'-ADP with the glycosyl torsion angle in the most commonly found anti range and the ribose at the C2'-endo conformation (Table 1).
The binding mode of 2',5'-ADP in RNase A molecules I and II differs considerably, as different phosphate groups of the inhibitor are bound in subsite P1. In molecule I, it is the 2'-phosphate that binds at P1 (Fig. 2B), while in RNase A molecule II the 5'-phosphate occupies the P1 subsite (Fig. 2C). In RNase A molecule I the side chain of His119 is found in conformation B (1 = -55°), while in RNase A molecule II adopts conformation A (1 = 157°). The adenine packs with its five-member ring against the imidazole ring of His119 and it is involved in 
– stacking interactions only in molecule II (Fig. 2C).
In molecule I, the adenine ring is in a different orientation but still parallel to the imidazole ring of His119 (Fig. 2B). The 5' and the 2'-phosphate groups of 2',5'-ADP in molecules I and II, respectively, point away from the protein, occupying two distinct positions 5 Å apart. These groups are exposed to the solvent and are not involved in any hydrogen bond interactions with RNase A. However, in molecule I, the 5' phosphate is oriented towards Lys7, the sole component of subsite P2. Although the closest distance of the phosphate oxygens to atom N
of Lys7 is 7 Å, it is sufficient for long-range coulombic interactions, which have been shown to play an important role in catalysis by RNase A (Fisher et al. 1998a,b).
The binding mode of 2',5'-ADP in molecule I resembles that of 3',5'-ADP, and it is similar to that observed previously for adenosine nucleotides bound at B2 in the RNase A complexes with d(pA)4 (McPherson et al. 1986), d(ApTpApApG) (Fontecilla-Camps et al. 1994), and d(CpA) (Zegers et al. 1994). The binding mode of 2',5'-ADP in molecule II is a novel mode observed for the first time. Upon superposition of the two RNase A molecules, the 5'-phosphate group of 2',5'-ADP in molecule I passes through the adenine ring of 2',5'-ADP in molecule II (Fig. 3A). However, apart from the side chain of His119, the rest of the active site residues are structurally conserved between molecules I and II (Fig. 3). The positions occupied by the 2' and the 5'-phosphate groups at P1 in the two binding modes are only 0.5 Å apart. In both binding modes the inhibitor is involved in hydrogen bond interactions with His12, His119, and Phe120, although through different atoms (Table 3). In addition, in molecule II, 2',5'-ADP is involved in hydrogen bonds with Gln11 and Asn71, whereas in molecule I it forms an additional hydrogen bond with Lys41 (Table 3).
|
|
). In molecule II, Ala4, Phe8, Gln11, His12, Lys41, Lys66, Asn67, Glu111, Gly112, Asn113, Val118, and Asp121 are involved in hydrogen bonds with 2',5'-ADP atoms, mediated by seven water molecules (Fig. 2C). The inhibitor and the protein participate in 22 van der Waals contacts, in molecule I, through residues His12, Lys41, Asn67, and His119. In molecule II, there are 36 van der Waals contacts between 10 protein residues and 14 inhibitor atoms.
The binding of 5'-ADP to RNase A
The 5'-ADP molecule is bound at the P1-B2 region of the RNase A active site. The electron density is of high quality, and all atoms of 5'-ADP are well defined (full occupancy) in molecule I of the crystallographic asymmetric unit (Fig. 1C). In molecule II, despite the 1.2 Å resolution data, the electron density for the inhibitor is relatively poor (occupancy 0.6). This partial binding, which has also been observed for U-2'-p and U-3'-p, as well as in previous binding studies with RNase A (Leonidas et al. 1997), might be attributed to the lattice contacts which limit access to the active site of molecule II of the asymmetric unit. Therefore, only molecule I will be considered for this complex throughout our discussion.
The conformation of 5'-ADP is similar to that of the adenosine 5'-pyrophosphate derivatives bound to RNase A (Leonidas et al. 1997, 1999; Jardine et al. 2001) and very different from all the other adenosine phosphonucleotides complexed with RNase A. The glycosyl torsion angle is at the unusual syn conformation, in contrast to 3',5'-ADP and 2',5'-ADP (Table 1; Fig. 1C). The ribose is at the C2'-endo conformation and the rest of the backbone and phosphate torsion angles have values frequently observed in protein bound nucleotides (Table 1). The syn conformation is rare in protein-bound adenosine nucleotides (Moodie and Thornton 1993), and has been previously observed in adenosine 5'-pyrophosphate derivatives bound to RNase A (Leonidas et al. 1997, 1999; Jardine et al. 2001).
The adenine packs with the six-member ring against the imidazole of His119 (conformation A, 1 = 158°), in contrast to 3',5'-ADP and 2',5'-ADP, and the N6 group is involved in hydrogen bond interactions with Asn67 and Asn71 (Table 4; Fig. 2D). 5'-ADP binds at the RNase A active site with the ß- rather than the -phosphate group at P1, and forms hydrogen bonds with Gln11, His12, Lys41, His119, and Phe120 (Fig. 2D). This mode of binding is reminiscent of the binding of the adenosine 5'-pyrophosphate derivatives to RNase A (Russo et al. 2001).
|
The binding of U-2'-p and U-3'-p to RNase A
Both U-2'-p and U-3'-p bind to the P1-B1 region of the RNase A active site adopting similar conformations and in a manner similar to that of uridine vanadate (UVan, a transition state analog) and other uridylyl nucleotides to RNase A (Gilliland 1997; Ladner et al. 1997). The two inhibitors, are well defined within the electron density map only in RNase A molecule I of the asymmetric unit (Fig. 1D,E). The electron density for both inhibitors is poor for molecule II, like in the RNase A–5'-ADP complex; hence, our study has been focused only in the complex of the inhibitors with molecule I.
The glycosyl torsion angle of uridine, in both inhibitors, is in the anti range, as found in most free and protein-bound pyrimidine nucleotides (Moodie and Thornton 1993). Torsion angles and 
are in the +sc and +ac range, respectively (Table 1). The ribose rings of U-2'-p and U-3'-p adopt the C3'-endo and the C2'-endo puckering, respectively, the two furanose puckerings most frequently observed in free and bound nucleotides (Moodie and Thornton 1993). The C2'-endo puckering has also been observed in 2'-deoxyuridine in the RNase A–pdUppA-3'-p and dUppA–3'-p complexes (Leonidas et al. 1999; Jardine et al. 2001), in cytidine in the RNase A–d(CpA) complex (Zegers et al. 1994), and in thymidine in the RNase A–d(ApTpApApG) complex (Fontecilla-Camps et al. 1994), while the C3'-endo has also been found in uridine in the RNase A–UVan complex (Wladkowski et al. 1998). This is different from the ribose puckerings of uridine in the d(UpcA) (C3'-exo) complex (Gilliland 1997) and in cytidine in the 2',5'-CpA (C4'-exo) and 3',5'-d(CpA) (C1'-exo) complexes (Toiron et al. 1996).
In both U-2'-p and U-3'-p complexes the uridine ring is packed against the phenyl ring of Phe120 and participates in hydrogen bond interactions with Thr45, the primary functional component of this subsite (Fig. 2E,F). The phosphate groups are in the P1 subsite occupying two distinct positions 2.0 Å apart (Fig. 3B). However, in both complexes, the phosphate group forms hydrogen bonds with residues Gln11, Lys41, and His119 (Table 5; Fig. 2E,F). In addition, the phosphate of U-2'-p forms two hydrogen bonds with residues His12 and Phe120 that might explain differences in the potency of the two uridylyl molecules (U-2'-p and U-3'-p are potent inhibitors of RNase A with Ki values of 7.1 and 82 µM, respectively; Anderson et al. 1968). There are 6 and 10 water molecules hydrogen-bonded to U-2'-p and U-3'-p, respectively (Table 5; Fig. 2E,F). Among them there is a water molecule that mediates interactions between atom O4 of uracil of U-2'-p and residues Asp83 and Ser 123. The same interactions are mediated through two water molecules in the U-3'-p complex. These water molecules might correspond to those proposed previously that adjust their donor/acceptor hydrogen bonding roles depending on whether uracil or cytosine is bound at the B1 subsite (Gilliland et al. 1994).
|
The binding of U-3'-p in the crystal of an RNase A variant, where Lys7, Arg10, and Lys66 were replaced by alanines, was studied previously (Fisher et al. 1998b). Superposition of the wild-type RNase A–U-3'-p complex structure of this study onto the K7A/R10A/K66A RNase A variant–U-3'-p complex structure reveals that U-3'-p binds in a similar mode to both enzymes (Fig. 4B). However, the location of U-3'-p in the active site, in the two complexes, differs by approximately 1.0 Å (Fig. 3C). In the variant complex structure His119 is in the B conformation (1 = -64°), in contrast to the native complex structure where it is found in conformation A. The rest of the active site residues in the two complexes superimpose well. The two uracil rings bind similarly in the B1 subsite, they are involved in stacking interactions with the phenyl ring of Phe120, and they are hydrogen-bonded to Thr45. In contrast, the position of the 3'-phosphate group is different in the two complexes (Fig. 3C). The ribose of U-3'-p in the variant complex structure adopts the C3'-endo puckering (C2'-endo in the native complex structure) orienting the 2'-hydroxyl and the 3'-phosphate groups in positions 2.5 Å and 2.2 Å away from their respective positions in the wild type complex structure (Fig. 3C). This difference in the ribose puckering could be attributed to steric hindrances imposed by the alternative conformations of His119. Thus, the 3'-phosphate group in the variant complex structure is placed between the side chains of His12 and His119, forming hydrogen bonds with their imidazoles and with the main chain nitrogen of Phe120. In the wild-type complex, the 3' phosphate forms a hydrogen bond with the side chain of His119 but no hydrogen bond interactions exist with His12 and Phe120 (Table 5). Instead, there is only a water-mediated interaction of the 3'-phosphate group to the side chain of His12. In addition, the 2'-hydroxyl group in the variant complex structure is hydrogen bonded to His12 N
2 and Lys41 N. In the wild-type complex structure, Lys41 N forms a hydrogen bond with O3' while O2' does not participate in any hydrogen bond interactions with the protein (Table 5). Overall, upon binding, U-3'-p forms five and six direct hydrogen bonds with the wild and variant RNase A, respectively (Table 5).
|
The different conformations adopted by the side chain of His119 in the two complex structures might also contribute to the difference in the affinity. Conformation A, found in the wild-type complex structure and also in the RNase A–UVan complex structure (Ladner et al. 1997), triggers binding of the phosphate group 2.2 Å away from the position it occupies in the variant–U-3'-p complex structure, towards the B1 subsite. It also promotes a C2'-endo puckering of the ribose, in contrast to a C3'-endo, in the variant. These conformations drive the uridine deeper, by approximately 1.0 Å, in the B1 pocket, in the native structure than in the variant structure, and allow it to form closer van der Waals contacts with the side chain of Phe120.
Superposition of the structures of U-2'-p and 2'-CMP RNase A (Lisgarten et al. 1993) complexes reveals that the nucleotide and phosphate moieties bind in similar locations to RNase A (Fig. 3D). Their riboses share the same C3'-endo conformation, and both inhibitors participate in a similar hydrogen-bonding network with RNase A. Structural comparison of the structures of U-3'-p and 3'-CMP (Zegers et al. 1994) complexes shows that their binding mode to RNase A is different (Fig. 3E). Their differences are similar to those observed when comparing the structures of the present RNase A–U-3'-p complex to the K7A/R10A/K66A RNase A–U-3'-p complex (Fig. 3C; Fisher et al. 1998b). Thus, in contrast to the U-3'-p complex where His119 is found in conformation A, in the 3'-CMP complex His119 adopts conformation B (Fig. 3E). The puckering of the riboses is also different: C2'-exo in 3'-CMP and C2'-endo in U-3'-p. The pyrimidine moieties of U-3'-p and 3'-CMP (both in anti conformation) bind in close positions (N4–O4 distance 1.0 Å) but their phosphate groups in the P1 subsite are quite apart (phosphorous-phosphorous distance: 2.4 Å). Thus, major differences are observed again in the interactions of the phosphate group in the active site, and as in the 3'-CMP complex structure, there are two additional hydrogen bonds to His12, and Phe120 and no hydrogen bonds with Gln11 when compared to the U-3'-p complex. The conformation of the side chain of Asp83 in the uridine complexes is different from its conformation in cytidine complexes (Lisgarten et al. 1993; Zegers et al. 1994). In the present uridine complexes, atom O of Thr45 is hydrogen bonded to atom O1 of Aps83, in agreement with previous observations with uridine vanadate (Ladner et al. 1997) and mutation results (delCardayre and Raines 1994, 1995), which indicated that this hydrogen bond strengthens preferentially the binding of uracil.
Comparison to eosinophil ribonucleases
The three central subsites, P1, B1, and B2 of the active site of RNase A, are conserved in EDN (Leonidas et al. 2001a) and ECP (Boix et al. 1999). Structural comparisons have shown that RNase A residues Gln11, His12, Lys41, and His119 of P1 are conserved as Gln14, His15, Lys38, and His129 in EDN and as Gln14, His15, Lys38, and His128 in ECP. Residues of the pyrimidine specific subsite B1 Thr45 and Phe120 in RNase A are conserved as Thr42 and Leu130 in EDN and as Thr42 and Leu129 in ECP. Furthermore, the purine binding subsite B2, constituted by residues Asn71, Glu111, and His119 in RNase A, is formed by the homologous residues Asn70, Asp112, and His128 (His129) in ECP and EDN, respectively (Boix et al. 1999; Leonidas et al. 2001a). The conformation of all the active site residues is conserved between RNase A, EDN, and ECP.
3',5'-ADP is a potent ribonucleolytic inhibitor with a Ki value of 5 µM for RNase A (Russo et al. 1997), 32 µM for EDN (Leonidas et al. 2001a), and 6–7 µM for ECP (Mohan et al. 2002). Superimposition of the crystal structure of the RNase–3',5'-ADP complex onto the structure of the EDN–3',5'-ADP complex (Leonidas et al. 2001a) reveals that the inhibitor binds similarly to the active site of these two RNases, although it occupies two distinct locations approximately 1.5 Å apart (Fig. 4A). The inhibitor adopts similar conformations when bound to either RNase A or EDN, adopting the energetically favored C2'-endo anti conformation (Moodie and Thornton 1993). The 5' phosphates bind at the P1 subsite but they occupy different locations with the phosphorous atoms located 1.0 Å apart, upon superposition of the two complex structures (Fig. 4A). Despite their different locations, the 5' phosphate groups are involved in analogous interactions with residues of the P1 subsite in the two enzymes. The only difference is the atom of the inhibitor that is hydrogen-bonded to His119 (EDN: His129). In the RNase A complex it is the 5' oxygen, while in the EDN complex it is one of the phosphate oxygens (Table 2). The adenine rings pack against the side chains of His119 or His129 with both histidines adopting conformation A (Fig. 4A). Differences in the hydrogen bond interactions of two adenines include a hydrogen bond of the N1 group with Asn70 in the EDN complex, not found in the RNase A complex, and a hydrogen bond of the N6 group with Gln69 of RNase A not observed in the EDN complex (Table 2). The 3' phosphates are located towards the N-terminal ends of RNase A and EDN, respectively (Fig. 5). Overall, the inhibitor is involved in seven hydrogen bond interactions with RNase A and EDN residues in the corresponding complexes (Table 2).
|
and have similar values, the glycosyl torsion angles have values between -66° to -112°, and the nucleotide in all three complexes adopts the anti conformation. The pseudorotation angles of the ribose in 2',5'-ADP also have similar values in all three complexes, and the ribose is found at the C2'-endo conformation.
The mode of binding of 2',5'-ADP to RNase A is different in the two molecules of the crystallographic asymmetric unit, as mentioned above. 2',5'-ADP binds to RNase A molecule I, as it binds to EDN and ECP (Fig. 4B,D). The 2'-phosphate occupies the P1 subsite and forms similar hydrogen bonds with protein residues in all three complexes (RNase A molecule I, EDN, and ECP; Table 3). The side chains of His119 in RNase A molecules I and II, (ECP: His128, EDN: His129) adopt different conformations. In the RNase A molecule I and in EDN, His119 adopts conformation B (Fig. 4B,D). In these complexes the adenine moiety of 2',5'-ADP forms stacking interactions with the imidazole ring of His119 (EDN: His129; Fig. 4B) and places its 2'-phosphate group in P1. In the ECP and RNase A molecule II 2',5'-ADP complexes, His128 (RNase A: His119) is in conformation A. In the ECP–2',5'-ADP complex the adenine moiety does not pack against the side chain of His128, but the 2'-phosphate still binds at P1 (Fig. 4D; Mohan et al. 2002). It is not clear why the adenine of 2',5'-ADP does not pack against the imidazole ring of His128 in ECP. Interestingly, the adenine ring of 2',5'-ADP packs against the imidazole ring of His119 in the RNase A molecule II–2',5'-ADP complex, but then it is the 5'-phosphate and not the 2'-phosphate that binds to subsite P1.
The 5'-phosphate groups of 2',5'-ADP in the RNase A molecule I and in the EDN complexes are oriented similarly pointing to the region of subsite P2 (Lys7 in RNase A and Trp10 in EDN). However, they are not involved in any hydrogen bonding interactions with the two proteins. In the ECP–2',5'-ADP complex (Mohan et al. 2002) the 5'-phosphate group makes a hydrogen bond interaction with Arg34, which is part of a novel P-1 subsite identified recently in EDN(Leonidas et al. 2001a) and ECP (Boix et al. 1999), and is located upstream of the cleavable phosphodiester bond (Table 3). There are also some other differences in the binding of 2',5'-ADP to RNase A, EDN, and ECP. In the complex with RNase A molecule II, atom N6 of the adenine forms a hydrogen bond with the side chain of Asn71 and in the EDN - 2',5'-ADP complex atom O3' of the ribose, forms a hydrogen bond with the main chain oxygen of Leu130 (Table 3).
The RNase A inhibitor, 5'-ADP, is more potent than 3',5'-ADP and 2',5'-ADP, with a Ki value of 1.2 µM at pH 5.9 (Russo et al. 1997). However, in EDN, it is less potent than 3',5'-ADP and 2',5'-ADP (Ki = 92 µM at pH 6.5; Leonidas et al. 2001a), while in ECP, it is almost as potent as 3',5'-ADP and 2',5'-ADP (Ki 2–3 µM at pH 6.0; Mohan et al. 2002). The inhibitor adopts two different conformations when bound to RNase A and EDN. In RNase A the adenosine is at the syn conformation ( = 73°), whereas in the EDN it is found at the anti conformation ( = -100°; Leonidas et al. 2001a). In both complexes the ribose adopts the C2'-endo conformation and the pseudorotation angles v0–v5 are broadly conserved. The backbone torsion angles , ß, and have also similar values, whereas the and pp differ, with those in the RNase A complex in the -sc and +ap range and those in the EDN complex in the +sc and +ap range, respectively. The mode of binding of 5'-ADP to RNase A and EDN is also different (Fig. 4C). In EDN, 5'-ADP is bound at the active site with the ß-phosphate at subsite P1, like in RNase A, but the adenosine is located in a region away from the B2 subsite close to, but not at B1 (in RNase A the adenosine binds at B2). Thus, the inhibitor is found in two opposite directions within the active site of the two enzymes.
The active-site residue His129 in EDN is found in the B conformation, while His119 in RNase A adopts conformation A (Fig. 4C). The ß-phosphate groups are engaged in similar hydrogen bonding networks with RNase A and EDN, involving residues His12, His119, and Phe120 (EDN: His15, His129, and Leu130; Table 4). There are also differences in the binding of the ß-phosphate group. In the EDN complex the ß-phosphate makes a hydrogen bond to Gln14 (RNase A: Gln11), whereas in the RNase A complex it is hydrogen-bonded to Lys41 (EDN: Lys38). The -phosphate group makes a single hydrogen bond interaction with Lys38 (RNase A: Lys41) in the EDN complex, while in the RNase A complex forms four hydrogen bonds.
In the EDN complex the adenine does not form any direct hydrogen bonding interaction with the protein, in contrast to the RNase A complex (Table 4). The binding of the adenosine in EDN is stabilized through two hydrogen bonds of the ribose with Gln40 and through van der Waals interactions of the adenine ring with Lys38, Gln40, and His82 (Leonidas et al. 2001a). The difference in the potency of 5'-ADP against RNase A and EDN (5'-ADP exhibits a 75 times lower Ki in RNase A than in EDN) might be attributed to differences in the polar interactions made by 5'-ADP in the two complexes.
Conclusions
The binding of five different phosphonucleotide inhibitors to RNase A was studied. Each inhibitor binds at the catalytic site by anchoring a phosphate group at the P1 subsite and adopts a completely different conformation (Fig. 5). The order of potency against RNase A for the five inhibitors studied is 5'-ADP > 3',5'-ADP > U-2'-p 
2',5'-ADP > U-3'-p. The occluded surface area of RNase A, calculated with the program GRASP (Nicholls and Honig 1991), by 5'-ADP, 3',5'-ADP, U-2'-p, 2',5'-ADP, and U-3'-p, is 638 Å2, 576 Å2, 500 Å2, 455 Å2 (molec I), 577 Å2 (molec II), and 497 Å2, respectively. Its size follows the potency of the inhibitors against the activity of RNase A. The extensive number of interactions of 5'-ADP with RNase A can explain its higher potency. Although 3',5'-ADP is a fragment of the physiological substrate of RNase A (RNA) and its binding mode should represent the binding of RNA in the active site, it is involved in fewer interactions with RNase A than 5'-ADP because only one of its phosphate groups is involved in hydrogen bond interactions with the enzyme. The diversity in the binding mode of 2',5'-ADP in RNase A (it is found in two different binding modes) may explain its high affinity for RNase A despite the smaller number of direct hydrogen bonds with RNase A in comparison to those of 3',5'-ADP. Significant differences on the phosphate binding of U-2'-p and U-3'-p in subsite P1 (two distinct locations), may contribute to the difference in the potency between the two inhibitors (U-2'-p has a 10 fold lower Ki for RNase A than U-3'-p; Anderson et al. 1968). The position in the U-2'-P complex allows the phosphate group to form more interactions with P1 residues than in the U-3'-p complex. Interestingly, similar difference in the locations of the phosphate exists also between the RNase A–2'CMP and the RNase A–3'CMP complexes (Howlin et al. 1987; Zegers et al. 1994) where 2'CMP has a 10-fold lower Ki for RNase than 3'CMP (Anderson et al. 1968).
The RNase A complex structures, described in this work, suggest how further development of tight binding inhibitors of RNases could be achieved through structure driven design. The high resolution of the crystal structures in the present study, allowed the identification of a large number of water molecules in the active site with bound inhibitors. Several of these water molecules mediate interactions between the inhibitors, and the protein and their positions could be the starting point for the design of more potent inhibitors. The adenine of 5'-ADP is involved in water-mediated interactions through two water molecules with the main chain of Asn67 and the side chain of Gln69. The 3' hydroxyl group of 2',5'-ADP in its complex with RNase A molecule II, is involved in water-mediated interactions with Glu111 and Val118. Two water molecules link the 5'-phosphate group in the same complex with the main-chain nitrogen of Ala4. The uracyl of U-2'-p is involved in water-mediated interactions with Ser123 and the side chain of Asp83. These water-mediated interactions are also conserved in the U-3'-p complex. All these water molecules indicate positions with high potential to form hydrogen bonds with the protein. Introduction of various substituents to the respective lead molecules could be used to decorate these ligands with groups that will allow them to reach those water positions and exploit their interactions with the protein, thus increasing their potency. The water network of the RNase A active site is partially conserved in the EDN active site as revealed by comparison of the atomic resolution structure of EDN (Swaminathan et al. 2002) with the structures reported here, further emphasizing its importance in the structure-based design of EDN inhibitors.
The structural comparison of the binding of analogous inhibitors in RNase A, EDN, and ECP has also implications for further design efforts of potent specific ribonucleolytic inhibitors of EDN and ECP. Interactions at P1 are broadly conserved for the three adenylic and the two uridylyl complexes with RNase A, for the three adenylic with EDN (Leonidas et al. 2001a), and for 2',5'-ADP with ECP (Mohan et al. 2002). Subsite P1 shows a clear preference for 5' phosphate groups over 3' because the binding of 3',5'-ADP in RNase A (both molecules) and EDN is very similar with the 5'-phosphate group always bound at P1. This preference is also supported by the binding mode observed by different 3',5'-ADP derivatives to RNase A, which is very similar to that for 3',5'-ADP. However, it is not clear whether a 5'- over a 2'-phosphate group is preferable, as the enzyme binds both phosphate groups equally well in different complexes. For example, in the case of 2',5'-ADP in RNase A molecule II, the 5'- is preferred while in RNase molecule I the 2'-phosphate group binds at P1.
The adenine base occupies a different location in each adenylic complex with RNase A, EDN, and ECP. The position observed in the 3',5'-ADP complex and in the 2',5'-ADP complex (RNase A molecule II) seems to be a substrate analogous position because it has also been observed in previous RNase A and EDN nucleotide complexes (Leonidas et al. 2001a). The additional positions observed in the RNase A–5'-ADP, the RNase A molecule I–2',5'-ADP, and the ECP–2',5'-ADP complexes seem to represent equivalent locations within the B2 subsite that can accommodate an adenine base, and in each case there are sufficient protein interactions to support the binding. Moreover, it seems that there is a correlation between the binding of a specific phosphate group (5'-or 2'-) and the position occupied by the adenine. Thus, when the 5'-phosphate group binds to P1, the nucleotide adopts a conformation that allows packing of the five-member ring of adenine against the imidazole of His119 (3',5'-ADP in RNase A, and in EDN; 2',5'-ADP in RNase A molecule II). In contrast, when the 2'-phosphate is bound to subsite P1 the nucleotide adopts various conformations placing the adenine in different locations in RNase A, EDN, and ECP.
The binding mode of 5'-ADP to RNase A confirms the preference of subsite P1 for the ß- rather than the -phosphate group when a pyrophosphate group is present in the inhibitor. This preference has been previously shown in complexes of RNase A with ppA-2'-p, ppA-3'-p, dUppA, and pdUppA-3'-p (Leonidas et al. 1997, 1999; Jardine et al. 2001). The binding of the ß-phosphate seems to force the nucleotide to adopt the unusual syn conformation and to place the six-member ring against the imidazole of His119. The only case where it adopts the most preferred conformation anti (Moodie and Thornton 1993) is in the EDN–5'-ADP complex (Leonidas et al. 2001a), and the adenosine is placed outside subsite B2 to an opposite direction, towards subsite B1. All these observations reveal a high flexibility of subsite B2, which can accommodate an adenine base in a variety of locations.
In contrast, subsite B1 seems to be more confined, and bound uridines are always placed in almost identical positions with the uridine ring being packed against the phenyl ring of Phe120 and the 2'-hydroxyl group in hydrogen bonding distance from the side chain atoms of Thr45. This has been observed in the current complexes of RNase A with U-2'-p and U-3'-p as well as in RNase A in complex with other uridylyl nucleotides (Leonidas et al. 1999; Jardine et al. 2001). However, the phosphate group binds to P1 despite its position in the ligand (either 2'- or 3'-). The binding of either the 2'- or the 3'-phosphate group to P1 does not seem to affect the binding mode of uridine to subsite B1, as shown in the RNase A complexes with U-2'-p and U-3'-p in contrast to adenylic inhibitors.
Comparative structural analysis of different complexes of nucleotide inhibitors to RNase A, EDN and ECP shows that the interactions at the P1 subsite are the main driving force for the binding of all the phosphonucleotides to RNases. Our results suggest that the specificity of P1 surpasses the specificity of the other subsites, and therefore, subsite P1 should be the target for the design of new RNase inhibitors. We also showed that each inhibitor does not necessarily bind to RNase A, EDN, and ECP in the same mode as in the case of 2',5'-ADP and 5'-ADP, and that subtle differences in the enzymic active sites can lead to profound alterations in the binding modes of an inhibitor to these RNases. These findings emphasize further the importance of obtaining direct structural information on the binding of each new inhibitor with RNase A and each RNase homolog in the process of structure-based inhibitor design.
|
Materials and methods |
|---|
|
TOPAbstractIntroductionResults and DiscussionMaterials and methodsReferences |
|---|
radiation. Data for the 5'-ADP and 2',5'-ADP complexes were collected to 1.2 Å resolution at 100 K at The European Synchrotron Radiation Facility (ESRF) at Grenoble (France) on station ID14-2 (
= 0.933 Å) using an ADSC Q4 CCD detector, and at the Protein Diffraction Beamline ( = 1.0006 Å) at Elettra-Trieste (Italy) using a MAR345 image plate, respectively. Three different data sets (589 frames in total) were collected for the 2',5'-ADP complex, to 1.2 Å, 1.48 Å, and to 2.3 Å resolution, to ensure completeness at the low resolution shell (92% for the 30.0–3.26 Å resolution shell). Similarly for the 5'-ADP complex, two different data sets (to 1.2 Å and 2.6 Å, 376 frames in total) were collected to ensure completeness at the low resolution shell (30.0–3.26 Å: 87.8%). Raw data were processed using the HKL program suite (Otwinowski and Minor 1997), and intensities were truncated to amplitudes by the TRUNCATE (French and Wilson 1978) program. Phases were obtained using the structure of free RNase A from monoclinic crystals (Leonidas et al. 1997) as a starting model. Alternate cycles of manual building with the program O (Jones et al. 1991), and refinement by torsion angle dynamics, conjugate gradient minimization, restrained individual B-factor refinement, and bulk solvent correction using the maximum likelihood target function as implemented in the program CNS v1.1 (Brünger et al. 1998) improved the model. Ligand molecules were included during the final stages of the refinement by use of their respective coordinates from the Protein Data Bank (ID codes: 2',5'-ADP, 1HI3
[PDB]
; 3',5'-ADP, 1HI4
[PDB]
; 5'-ADP, 1HI5
[PDB]
[Leonidas et al. 2001a]; U-3'-p, 4RSK
[PDB]
[Fisher et al. 1998b]). A model of U-2'-p, was generated using the program SYBYL (Tripos Associates Inc.). Furthermore, the 1.2 Å resolution data from the 2',5'-ADP and 5'-ADP complexes enabled the anisotropic refinement of temperature factors with the program REFMAC (Murshudov et al. 1997). Details of data processing and refinement statistics are provided in Table 6.
|
|
Acknowledgments |
|---|
The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.
|
References |
|---|
|
TOPAbstractIntroductionResults and DiscussionMaterials and methodsReferences |
|---|
Anderson, D.G., Hammes, G.G., and Walz, F.G. 1968. Binding of phosphate ligands to Ribonuclease A. Biochemistry 7: 1637–1645.[CrossRef][Medline]
Berisio, R., Lamzin, V.S., Sica, F., Wilson, K.S., Zagari, A., and Mazzarella, L. 1999. Protein titration in the crystal state. J. Mol. Biol. 292: 845–854.[CrossRef][Medline]
Berisio, R., Sica, F., Lamzin, V.S., Wilson, K.S., Zagari, A., and Mazzarella, L. 2002. Atomic resolution structures of ribonuclease A at six pH values. Acta Crystallogr. D 58: 441–450.[CrossRef][Medline]
Boix, E., Leonidas, D.D., Nikolovski, Z., Nogues, M.V., Cuchillo, C.M., and Acharya, K.R. 1999. Crystal structure of eosinophil cationic protein at 2.4 Å resolution. Biochemistry 38: 16794–16801.[CrossRef][Medline]
Borkakoti, N., Moss, D.A., and Palmer, R.A. 1982. Ribonuclease A: Least squares refinement of structure at 1.45 Å resolution. Acta Crystallogr. B 38: 2210–2217.[CrossRef]
Brünger, A.T. 1992. Free R value: A novel statistical quantity for assessing the accuracy of crystal structures. Nature 355: 472–475.[CrossRef]
Brünger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-Kunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges, M., Pannu, N.S., et al. 1998. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D 54: 905–921.[CrossRef][Medline]
D’Alessio, G. and Riordan, J.F. 1997. Ribonucleases: Structure and functions. Academic Press, New York.
delCardayre, S.B. and Raines, R.T. 1994. Structural determinants of enzymatic processivity. Biochemistry 33: 6031–6037.[CrossRef][Medline]
———. 1995. A residue to residue hydrogen bond mediates the nucleotide specificity of ribonuclease A. J. Mol. Biol. 252: 328–336.[CrossRef][Medline]
deMel, V.S.J., Doscher, M.S., Martin, P.D., and Edwards, B.F.P. 1994. The occupancy of two distinct conformations by active-site histidine-119 in crystals of Ribonuclease is modulated by pH. FEBS Lett. 349: 155–160.[CrossRef][Medline]
Domachowske, J.B., Bonville, C.A., Dyer, K.D., and Rosenberg, H.F. 1998a. Evolution of antiviral activity in the ribonuclease A gene superfamily: Evidence for a specific interaction between eosinophil-derived neurotoxin (EDN/RNase 2) and respiratory syncytial virus. Nucleic Acids Res. 26: 5327–5332.
Domachowske, J.B., Dyer, K.D., Bonville, C.A., and Rosenberg, H.F. 1998b. Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J. Infect. Dis. 177: 1458–1464.[Medline]
Esnouf, R.M. 1997. An extensively modified version of Molscript that includes greatly enhanced coloring capabilities. J. Mol. Graphics Modelling 15: 132–134.[CrossRef][Medline]
Fedorov, A.A., Joseph-McCarthy, D., Fedorov, E., Sirakova, D., Graf, I., and Almo, S.C. 1996. Ionic interactions in crystalline bovine pancreatic ribonuclease A. Biochemistry 35: 15962–15979.[CrossRef][Medline]
Fett, J.W., Strydom, D.J., Lobb, R.R., Alderman, E.M., Bethune, J.L., Riordan, J.F., and Vallee, B.L. 1985. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma-cells. Biochemistry 24: 5480–5486.[CrossRef][Medline]
Fisher, B.M., Ha, J.H., and Raines, R.T. 1998a. Coulombic forces in protein–RNA interactions: Binding and cleavage by ribonuclease A and variants at Lys7, Arg10, and Lys66. Biochemistry 37: 12121–12132.[CrossRef][Medline]
Fisher, B.M., Schultz, L.W., and Raines, R.T. 1998b. Coulombic effects of remote subsites on the active site of ribonuclease A. Biochemistry 37: 17386–17401.[CrossRef][Medline]
level, and the refined structure of the inhibitor is shown. General numbering scheme for each inhibitor is also shown. The figure was prepared with BOBSCRIPT (
